Search

Displaying results 1641 - 1650 of 10000 in total
  1. Drug

    Cerivastatin

    go.drugbank.com/drugs/DB00439
    ApprovedWithdrawn

    On August 8, 2001 the U.S. … Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2B6 Inducers
  2. Drug

    Pargyline

    go.drugbank.com/drugs/DB01626
    Approved

    Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.

    Categories: MAO Inhibitors and Diuretics, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  3. Drug

    Tirzepatide

    go.drugbank.com/drugs/DB15171
    ApprovedInvestigational

    [A246265] Tirzepatide was approved by the FDA on May 13, 2022, under the brand name MOUNJARO by the FDA for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor … Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

    Categories: GLP-1 Agonists, Receptors, G-Protein-CoupledProducts: Mounjaro 5 mg/0,5 ml Enjeksiyonluk Çözelti, 1 ADET, Mounjaro 5 mg/0,5 ml Enjeksiyonluk Çözelti, 4 ADET
  4. Target

    Thiosulfate:glutathione sulfurtransferase

    go.drugbank.com/bio_entities/BE0010200
    EnzymeHumans

    Thiosulfate:glutathione sulfurtransferase (TST) required to produce S-sulfanylglutathione (GSS(-)), a central intermediate in hydrogen sulfide metabolism (PubMed:24981631). Provides the link between the first step in mammalian H(2)S meta...

    Synonyms: KAT
  5. Drug

    Penpulimab

    go.drugbank.com/drugs/DB16747
    ApprovedInvestigational

    The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events. … Penpulimab is a humanized monoclonal IgG1 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1).

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, Programmed Death Receptor-1 Blocking Antibody
  6. Drug

    Lepirudin

    go.drugbank.com/drugs/DB00001
    ApprovedWithdrawn

    [A246609] Lepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications. … [A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]

    Synonyms: R-hirudin, Hirudin variant-1
  7. Drug

    Blinatumomab

    go.drugbank.com/drugs/DB09052
    ApprovedInvestigational

    Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through … [A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells.

    Categories: Bispecific CD19-directed CD3-directed T Cell EngagerProducts: BLINCYTO® 38.5 MCG/VIAL, BLİNCYTO 38,5 MCG İNFÜZYONLUK ÇÖZELTİ İÇİN KONSANTRE TOZ VE ÇÖZELTİ, 1 ADET
  8. Drug

    Tolbutamide

    go.drugbank.com/drugs/DB01124
    Approved

    Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C18 SubstratesSynonyms: 3-(p-Tolyl-4-sulfonyl)-1-butylurea, 1-Butyl-3-(p-tolylsulfonyl)urea
  9. Drug

    Calcium ascorbate

    go.drugbank.com/drugs/DB14483
    ApprovedNutraceutical

    Mixtures: Supplements De Vitamines Et Mineraux, Acti-MN + B1 + C CapletCategories: Vitamin C and analogues, Compounds used in a research, industrial, or household setting
  10. Drug

    Dacarbazine

    go.drugbank.com/drugs/DB00851
    ApprovedInvestigational

    An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564).

    Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic IndexSynonyms: 4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide, 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide